Ignite Creation Date:
2024-05-05 @ 5:09 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00392080
Status:
COMPLETED
Last Update Posted:
2008-03-24
First Post:
2006-10-23
Brief Title:
A Study Of The Effect Of CJ-023423 On The Incidence Of Stomach Ulcers
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Multicenter Randomized Placebo And Active-Controlled Study Of The Effect Of CJ-023423 On The Incidence Gastroduodenal Endoscopic Ulcers In Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CJ-023423 is a new medication being developed as an anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis OA The purpose of this study is to evaluate whether patients treated with CJ-023423 for 7 days 14 doses have fewer gastrointestinal ulcers compared to patients treated with naproxen and placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None